drugset
drugset / Trial / NCT03233035

Low Dose Ketamine Intra Nasal Traumatology

NCT03233035 ↗

Phase 2 Completed 1102 enrolled University of Monastir
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.

Timeline

Start
2018-01-01
Primary completion
2018-12-01
Completion
2018-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 25 mg Intranasal

Indications

No indication recorded.